Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $15.9400 (0.19%) ($15.6800 - $16.4800) on Tue. Dec. 8, 2015. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.22% (three month average) | RSI | 60 | Latest Price | $15.9400(0.19%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.7% a day on average for past five trading days. | Weekly Trend | ADMS advances 1.3% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(32%) IBB(30%) ARKG(22%) IWO(22%) XOP(22%) | Factors Impacting ADMS price | ADMS will decline at least -1.61% in a week (0% probabilities). VIXM(-14%) BNDX(-10%) TLT(-7%) SHY(-7%) UUP(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.61% (StdDev 3.22%) | Hourly BBV | 0 () | Intraday Trend | 1.7% | | | |
|
5 Day Moving Average | $16.21(-1.67%) | 10 Day Moving Average | $16.15(-1.3%) | 20 Day Moving Average | $15.92(0.13%) | To recent high | -24.6% | To recent low | 19.6% | Market Cap | $451m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |